CYP2S1

Across TCGA pan-cancer cohorts, CYP2S1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CYP2S1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CYP2S1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYP2S1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, OV, and GBM are the cancer types where CYP2S1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.938	0.752	<.001	52	view →
OV	DFS	Median	All	0.854	1.000	.025	4	view →
GBM	OS	Median	All	0.444	0.601	.038	3	view →
UCEC	DFS	Quartile	All	0.764	0.960	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CYP2S1–PDAC (OS)

Open the PDAC breakdown →